GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Cyclically Adjusted Revenue per Share

Sorrento Therapeutics (LTS:0L85) Cyclically Adjusted Revenue per Share : $0.40 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sorrento Therapeutics's adjusted revenue per share for the three months ended in Jun. 2023 was $0.027. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.40 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Sorrento Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sorrento Therapeutics was 62.00% per year. The lowest was -1.00% per year. And the median was 18.60% per year.

As of today (2024-05-25), Sorrento Therapeutics's current stock price is $0.015. Sorrento Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $0.40. Sorrento Therapeutics's Cyclically Adjusted PS Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sorrento Therapeutics was 296.50. The lowest was 0.02. And the median was 18.00.


Sorrento Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted Revenue per Share Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.36 0.33 0.38 0.39

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.41 0.39 0.42 0.40

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sorrento Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sorrento Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.027/128.7287*128.7287
=0.027

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.006 98.790 0.008
201312 0.005 98.326 0.007
201403 0.042 99.695 0.054
201406 0.031 100.560 0.040
201409 0.045 100.428 0.058
201412 0.027 99.070 0.035
201503 0.027 99.621 0.035
201506 0.032 100.684 0.041
201509 0.030 100.392 0.038
201512 0.035 99.792 0.045
201603 0.026 100.470 0.033
201606 0.019 101.688 0.024
201609 0.034 101.861 0.043
201612 0.068 101.863 0.086
201703 0.096 102.862 0.120
201706 0.066 103.349 0.082
201709 1.586 104.136 1.961
201712 0.245 104.011 0.303
201803 0.074 105.290 0.090
201806 0.039 106.317 0.047
201809 0.035 106.507 0.042
201812 0.057 105.998 0.069
201903 0.050 107.251 0.060
201906 0.049 108.070 0.058
201909 0.041 108.329 0.049
201912 0.079 108.420 0.094
202003 0.042 108.902 0.050
202006 0.042 108.767 0.050
202009 0.046 109.815 0.054
202012 0.043 109.897 0.050
202103 0.048 111.754 0.055
202106 0.047 114.631 0.053
202109 0.040 115.734 0.044
202112 0.042 117.630 0.046
202203 0.055 121.301 0.058
202206 0.028 125.017 0.029
202209 0.039 125.227 0.040
202212 0.032 125.222 0.033
202303 0.030 127.348 0.030
202306 0.027 128.729 0.027

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sorrento Therapeutics  (LTS:0L85) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sorrento Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.015/0.4
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sorrento Therapeutics was 296.50. The lowest was 0.02. And the median was 18.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sorrento Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Industry
Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines